Current and Emerging BTK Inhibitors for Chronic Lymphocytic Leukemia
Researchers sought to determine the landscape of BTK inhibitors for treating patients with CLL.
Leukemia
LEUKEMIA
FEATURE
LATEST ARTICLES
Surface IgM Signaling Capacity Associated With Ibrutinib Resistance in Chronic Lymphocytic Leukemia
Researchers sought to determine whether IgM levels would impact treatment responsiveness to ibrutinib in patients with CLL.
Triplet Falls Short in Relapsed/Refractory Chronic Lymphocytic Leukemia
Combination acalabrutinib, obinutuzumab, and venetoclax did not meet the prespecified activity threshold in the CLL2-BAAG trial.
Long-Term Follow-Up Shows Continued Survival Benefit With Ibrutinib/Rituximab in Chronic Lymphocytic Leukemia
Researchers sought to determine whether there was a sustained benefit for patients with CLL receiving treatment with ibrutinib plus rituximab.
PFS Not Associated With 1-Year Depth of Response to Ibrutinib in Chronic Lymphocytic Leukemia
Researchers sought to determine whether there was a difference in PFS based on depth of response with ibrutinib at 1 year in patients with CLL.
Ferroptosis-Related Gene Expression May Predict Outcomes in Chronic Lymphocytic Leukemia
Researchers sought to determine whether there was an association between ferroptosis-related genes and prognosis for patients with CLL.
FDA Warns of Increased Side Effects, Death Risk With Duvelisib
Copiktra is an oral inhibitor of phosphoinositide 3-kinase.
Bacterial Coinfection Associated With Poor COVID-19 Outcomes in Chronic Lymphocytic Leukemia
Researchers sought to determine the case fatality rate in patients with CLL who were infected with SARS-CoV-2.
TAp63 Expression Levels May Drive Disease Aggressiveness in Chronic Lymphocytic Leukemia
Researchers sought to determine whether there was a link between TAp63 and disease aggressiveness in patients with CLL.
Clinical Advantages: Targeting BTK in CLL
Chronic lymphocytic leukemia (CLL) is a chronic incurable mature B-cell neoplasm that often does not require immediate treatment; however, when patients experience symptoms, such as anemia, cytopenias, or bulky lymphadenopathy, therapy is required. During a presentation at the 2022 Oncology Nurse Advisor Summit, Laura J. Zitella, MS, RN, ACNP-BC, AOCN, an associate clinical professor at…
Moderna COVID-19 Vaccine May Be More Effective in CLL Patients
Patients with CLL were significantly more likely to have an antibody response to the Moderna vaccine than to the Pfizer-BioNTech vaccine.
Venetoclax Plus Dose-Adjusted R-EPOCH Yields Deep, Durable Responses in Patients With Richter Syndrome
Researchers sought to determine whether adding venetoclax to R-EPOCH would induce durable responses in patients with Richter syndrome.
Treatment With Obinutuzumab Makes Earlier Ibrutinib Discontinuation Possible in Chronic Lymphocytic Leukemia
Researchers sought to determine whether adding obinutuzumab to ibrutinib for patients with CLL would permit earlier ibrutinib discontinuation.
CAR-T Therapy Ushering in a New Era of Precision Medicine for Patients With Chronic Lymphocytic Leukemia
Researchers are working towards developing CAR-T therapy to provide longer and more durable responses for patients with CLL.
Third COVID-19 Vaccine Dose May Induce Response in Subset of Patients With Chronic Lymphocytic Leukemia
Researchers sought to determine whether a third dose of the BNT162b2 mRNA vaccine against COVID-19 may induce an antibody response in patients with CLL or SLL.
Less Intensive Monitoring of Venetoclax May be Safe in Low-Risk CLL
A retrospective review of data from patients with CLL demonstrated varied adherence to guidelines for ramp up initiation and laboratory monitoring.
Age Is Not an Independent Predictor of Outcomes in Chronic Lymphocytic Leukemia Treated With Ibrutinib
Researchers sought to determine whether age impacts survival in patients with CLL undergoing treatment with ibrutinib.
Prognostic Index May ID CLL Patients Who Will Not Need Treatment
Novel prognostic index CLL-WONT identifies patients with chronic lymphocytic leukemia who are at low risk for ever requiring treatment
MRD Status May Not Predict PFS for Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib
Researchers sought to determine whether MRD negativity could predict PFS in patients with CLL treated with ibrutinib.
Ibrutinib Not Recommended Over ‘Watch and Wait’ in Asymptomatic, Early CLL
Ibrutinib improved event-free survival, but its effect on overall survival is unclear.
CLL Treatment May Increase Risk of Death From COVID-19
There were no significant differences by treatment type.
Ponatinib Yields Benefits Across 3 Dosage Regimens in Chronic-Phase Chronic Myeloid Leukemia
Researchers sought to determine whether different doses of ponatinib would have benefit for patients with resistant chronic-phase chronic myeloid leukemia.
MRD Dynamics After Fixed-Duration Treatment in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Researchers sought to determine whether MRD would improve after fixed-duration treatment with venetoclax and obinutuzumab therapy in patients with CLL.
GST Polymorphisms Are Associated With Risk of B-Cell Acute Lymphocytic Leukemia
Researchers sought to determine the impact of GST polymorphisms on the risk of B-ALL.
Progression After BTK Inhibitor and Venetoclax Progression Linked With Poor Outcomes in Chronic Lymphocytic Leukemia
Researchers sought to determine whether patients with CLL whose disease develops resistance to both BTK and BCL2 inhibition have a poor prognosis.
F2-ISoP Levels in CSF a Potential Biomarker of Therapy-Related Cognitive Outcomes in Children With ALL
Researchers sought to determine if F2-ISoP levels could be a biomarker for cognitive dysfunction in children with ALL.
Cell-in-Cell Sheltering May Have Implications in Drug Resistance
Researchers sought to determine whether cell-in-cell interactions would have a role in drug resistance.
Acalabrutinib, Venetoclax, Obinutuzumab Shows Promise as Frontline Therapy for Chronic Lymphocytic Leukemia
Researchers sought to determine whether acalabrutinib, venetoclax, and obinutuzumab would be a helpful option for frontline treatment of CLL.
Antibody Responses After COVID-19 Vaccination in Patients With Chronic Lymphocytic Leukemia
Researchers sought to determine the efficacy of the COVID-19 vaccine in patients with CLL.
MAPK Pathway Linked to Resistance to Phosphatidylinositol 3-Kinase Inhibition in Patients With Chronic Lymphocytic Leukemia
Researchers sought to determine whether activation of MAPK pathway genes may play a role in resistance to PI3K inhibitor therapy in patients with CLL.
Registry Data Support Use of Ponatinib in CML, Ph+ ALL Resistant or Intolerant to Tyrosine Kinase Inhibitors
An analysis of a registry of patients with CML and Philadelphia chromosome-positive ALL demonstrated that ponatinib is efficacious in those with relapsed or refractory disease.
Therapeutic Drug Monitoring Improved Incidence of Pleural Effusion With Dasatinib for CP-CML
A dose-reduction strategy in patients with CP-CML receiving dasatinib was shown to be feasible and may reduce adverse effects in these patients.
Treatment Strategies and Challenges in Chronic Lymphocytic Leukemia
Researchers sought to clarify the current treatment strategies and challenges for patients with chronic lymphocytic leukemia.
Venetoclax Plus Obinutuzumab Prolongs PFS, Not OS, in Chronic Lymphocytic Leukemia
At 4 years, there was no significant difference in overall survival.
Acalabrutinib Seems Safe and Efficacious in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia
Researchers sought to determine whether acalabrutinib would be safe and effective in patients with treatment-naïve CLL who declined or were in ineligible for chemotherapy.
CAR T Cell Therapy May Not Improve Survival vs Chemotherapy in B-ALL After Allo-HSCT
Researchers sought to determine whether CAR T therapy would have a better result than pretransplant chemotherapy in patients with B-ALL undergoing allo-HSCT.
Umbralisib Shows Promise Among Patients With CLL Intolerant to BTK, PI3K Inhibitors
Researchers sought to determine whether umbralisib would be an effective treatment option for patients with CLL who cannot tolerate BTK or PI3Kδ inhibitors.
CLL/SLL: Ibrutinib, Venetoclax Therapy May Improve Outcomes in First Line
The tumor lysis syndrome risk decreased for 84.6% of patients in the ibrutinib/venetoclax group.
MEK Inhibitors May Overcome Resistance to PI3K Inhibitors in Chronic Lymphocytic Leukemia
Activation of the MAPK/ERK pathway mediates resistance to PI3K inhibitors, researchers found.
Calorie Restriction May Increase Efficacy of Chemotherapy in Younger Patients With B-ALL
The IDEAL trial found that adolescents and young adults with B-cell acute lymphoblastic leukemia may benefit from restrictive diets and increased exercise.
Chimeric Antigen Receptor T-Cell Therapy Shows Positive Results in Pediatric Patients With B-Cell ALL
Researchers sought to determine the long-term safety and efficacy of KTE-X19 in pediatric and adolescent patients with relapsed or refractory B-cell acute lymphoblastic leukemia.
Upfront Low-Dose Chemo-Immunotherapy Safe, Effective for Elderly With CLL
A study was conducted to assess the safety and efficacy of fludarabine and cyclophosphamide combined with rituximab for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma in elderly patients and those with comorbid conditions.
Certain Mutations May Be Associated With Infection Risk for Patients With Chronic Lymphocytic Leukemia
Researchers sought to determine factors that may impact infection risk in patients with CLL.
Anti-CD20 Antibody Improved Response to Ibrutinib in High-Risk R/R CLL
Investigators conducted a randomized controlled trial to determine whether the addition of ublituximab to treatment with ibrutinib improved outcomes in patients with relapsed or refractory chronic lymphocytic leukemia.
BTK Inhibitors for CLL Lower Response to Some Vaccines
A team of investigators conducted a phase 2 trial to assess outcomes of hepatitis C virus and varicella zoster vaccination in patients with treatment-naive CLL or those on BTK inhibitor therapy.
The Role of Early Intervention in the Treatment of Early-Stage CLL
There is a need for further investigation of early intervention options for patients with early-stage CLL.
Blinatumomab Improved Survival for Patients With B-Cell ALL, but Not Significantly
Researchers sought to determine if immunotherapy including blinatumomab could improve disease-free survival for patients with B-cell ALL.
Lenalidomide Maintenance Therapy Linked With B-Cell Acute Lymphoblastic Leukemia in Patients With Chronic Lymphocytic Leukemia
Researchers sought to describe a potential link between treatment with lenalidomide and development of B-cell ALL in patients with CLL.
TBI Conditioning Before Stem Cell Transplantation Improves Survival in Pediatric ALL
Researchers sought to determine whether pediatric patients with ALL would have better OS if they received TBI prior to HSCT.
Leukemia: Fact Sheet for Patients
Almost everyone has heard of leukemia, but most people do not have a good understanding of this complex disease. How can healthcare providers explain the basics of leukemia to their patients?
Pyridoxine Plus Pyridostigmine Beneficial for Neurotoxicity in ALL
A team of investigators prospectively evaluated pediatric patients with ALL to determine the effectiveness of pyridoxine (vitamin B6) plus pyridostigmine therapy for vincristine-induced neurotoxicity.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Leukemia
Loading... 
Loading...